Tanshinone IIA Ameliorates Progression of CAD Through Regulating Cardiac H9c2 Cells Proliferation and Apoptosis by miR-133a-3p/EGFR Axis

References

• JiangL, KrumholzHM, LiX, LiJ, HuS. Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system. Lancet. 2015;386(10002):1493–1505. doi:10.1016/S0140-6736(15)00343-826466053
   PubMed Web of Science ®Google Scholar
• RothGA, JohnsonC, AbajobirA, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. doi:10.1016/j.jacc.2017.04.05228527533
   PubMed Web of Science ®Google Scholar
• BhatnagarP, WickramasingheK, WilliamsJ, RaynerM, TownsendN. The epidemiology of cardiovascular disease in the UK 2014. Heart. 2015;101(15):1182–1189. doi:10.1136/heartjnl-2015-30751626041770
   PubMed Web of Science ®Google Scholar
• MathersCDLD, LoncarD. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):442. doi:10.1371/journal.pmed.0030442
   PubMed Web of Science ®Google Scholar
• SinghS, KulloIJ, PardiDS, LoftusEV Jr. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol. 2015;12(10002):26–35. doi:10.1038/nrgastro.2014.20225446727
   PubMed Web of Science ®Google Scholar
• ZhaoZQ, Vinten-JohansenJ. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res. 2002;55(3):438–455. doi:10.1016/S0008-6363(02)00442-X12160941
   PubMed Web of Science ®Google Scholar
• ZhouL. Zuo Z and Chow MS: Danshen: an overview of its chemistry, pharmacology, pharmacokinetics and clinical use. J Clin Pharmacol. 2005;45(12):1345–1359. doi:10.1177/009127000528263016291709
   PubMed Web of Science ®Google Scholar
• FishJM, WelchonsDR, KimYS, LeeSH, HoW-K, AntzelevitchC. Ho WK and Antzelevitch C: dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation. 2006;113(11):1393–1400. doi:10.1161/CIRCULATIONAHA.105.60169016534004
   PubMed Web of Science ®Google Scholar
• AdamsJD, WangR, YangJ, et al. Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chin Med. 2006;1(1):3. doi:10.1186/1749-8546-1-317302964
   PubMedGoogle Scholar
• PangH, HanB, YuT, PengZ. The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy. PLoS One. 2014;9(3):e92216. doi:10.1371/journal.pone.009221624647357
   PubMed Web of Science ®Google Scholar
• XuS, LiuP. Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat. 2013;23(2):149–153. doi:10.1517/13543776.2013.74399523231009
   PubMed Web of Science ®Google Scholar
• GaoJ, YangG, PiR, et al. Chen S and Liu P: tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res. 2008;151(2):79–87. doi:10.1016/j.trsl.2007.11.00518201675
   PubMed Web of Science ®Google Scholar
• YangR, LiuA, MaX, LiL, SuD, LiuJ. Su D and Liu J: sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol. 2008;51(4):396–401. doi:10.1097/FJC.0b013e318167143918427283
   PubMed Web of Science ®Google Scholar
• BaehreckeEH. MiRNAs: micro managers of programmed cell death. Curr Biol. 2003;13(12):R473–R475. doi:10.1016/S0960-9822(03)00405-612814564
   PubMed Web of Science ®Google Scholar
• MendellJT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005;4(9):1179–1184. doi:10.4161/cc.4.9.203216096373
   PubMed Web of Science ®Google Scholar
• Landskroner-EigerS, MonekeI, SessaWC. miRNAs as Modulators of Angiogenesis. Cold Spring Harb Perspect Med. 2013;3(2):a006643. doi:10.1101/cshperspect.a00664323169571
   PubMed Web of Science ®Google Scholar
• SongT, YaoY, WangT, HuangH, XiaH. Tanshinone IIA ameliorates apoptosis of myocardiocytes by up-regulation of miR-133 and suppression of Caspase-9. Eur J Pharmacol. 2017;815:343–350. doi:10.1016/j.ejphar.2017.08.04128867607
   PubMed Web of Science ®Google Scholar
• GuY, LiangZ, WangH, et al. Tanshinone IIA protects H9c2 cells from oxidative stress-induced cell death via microRNA-133upregulation and Akt activation. Exp Ther Med. 2016;12(2):1147–1152. doi:10.3892/etm.2016.340027446335
   PubMed Web of Science ®Google Scholar
• LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.126211846609
   PubMed Web of Science ®Google Scholar
• MakkiN, ThielKW, MillerF. Miller FJ Jr: the epidermal growth factor receptor and its ligands in cardiovascular disease. Int J Mol Sci. 2013;14(10):20597–20613. doi:10.3390/ijms14102059724132149
   PubMed Web of Science ®Google Scholar
• SchreierB, GekleM, GrossmannC. Gekle M and Grossmann C: role of epidermal growth factor receptor in vascular structure and function. Curr Opin Nephrol Hypertens. 2014;23(2):113–121. doi:10.1097/01.mnh.0000441152.62943.2924401788
   PubMed Web of Science ®Google Scholar
• WangS, HeW, WangC. MiR-23a regulates the vasculogenesis of coronary artery disease by targeting epidermal growth factor receptor. Cardiovasc Ther. 2016;34(4):199–208. doi:10.1111/1755-5922.1218727085964
   PubMed Web of Science ®Google Scholar
• McCarthyNJ, BennettMR. The regulation of vascular smooth muscle cell apoptosis. Cardiovasc Res. 2000;45(3):747–755. doi:10.1016/S0008-6363(99)00275-810728397
   PubMed Web of Science ®Google Scholar
• SamarakoonR, HigginsPJ. Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost. 2008;100(12):976–983. doi:10.1160/TH08-05-027319132220
   PubMed Web of Science ®Google Scholar
• LeszczynskaKB, FoskolouIP, AbrahamAG, et al. Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. J Clin Invest. 2015;125(6):2385–2398. doi:10.1172/JCI8040225961455
   PubMed Web of Science ®Google Scholar
• ValenteLJ, GrabowS, VandenbergCJ, StrasserA, JanicA. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. Oncogene. 2016;35(29):3866–3871. doi:10.1038/onc.2015.45726640149
   PubMed Web of Science ®Google Scholar
• CzabotarPE, LesseneG, StrasserA, AdamsJM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63. doi:10.1038/nrm372224355989
   PubMed Web of Science ®Google Scholar
• PoznerA, TerooateaTW, Buck-KoehntopBA. Cell-specific kaiso (ZBTB33) regulation of cell cycle through cyclin D1 and cyclin E1. J Biol Chem. 2016;291(47):24538–24550. doi:10.1074/jbc.M116.74637027694442
   PubMed Web of Science ®Google Scholar